Abstract
Multiple Pathways Compensate for Antisense Suppression of Bcl-2 in LNCaP Cells Contributing to Tumor Resistance Antisense oligonucleotides (oligos) have been employed against in vivo and in vitro prostate cancer models targeting growth regulatory proteins. While most oligos target growth factors or their receptors, others are directed against apoptosis inhibitors and mediators of androgen action. Those which suppress Bcl-2 activity have even reached clinical trials in prostate cancer patients. We previously evaluated a set of oligos which targeted and comparably suppressed the expression of the apoptosis inhibitor protein Bcl-2. LNCaP cells adapted to this restoration of apoptosis with suppression of caspase-3 (another apoptosis inhibitor). In this continuing study we evaluated additional proteins associated with tumor progression and found the expression of the Androgen Receptor (AR), its p300 and IL-6 co-activators and the v-myc oncogene are enhanced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
